Post-Approval, Observational Study with Garenoxacin a Newer des-fl uoroquinolone in Uncomplicated Urinary Tract Infections in Vadodara, India.
Loading...
Date
2015-01
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Background: Urinary tract infection (UTI) is one of the most important global health issues, which has raised the morbidity and
mortality rates in both the genders. Strategies that are proposed in the management of UTIs include use of empirical antibiotics with
a broad spectrum of coverage. Urine specimen culture plays a pivot role to evaluate the organism responsible for the pathogenesis.
Methods: This observational study was conducted at Vadodara comprised of 50 patients suffering from UTI. All the patients that
included in the study were examined for side-effects during the entire period of the drug therapy. Clinical response was judged
by subjective assessment for control of presenting symptoms.
Results: Data were obtained from 50 patients. Garenoxacin was prescribed as a fi rst-line therapy to the patients with UTI. Four
patients received the drug for 5 days and 44 patients received the drug for 7 days. Escherichia coli was the most common organism
obtained from the urine culture, followed by Staphylococcus saprophyticus and Enterobacter species. Clinical cure/improved
was established in 98% of cases. One case of therapy failure was reported. Negligible side-effects such as nausea, vomiting,
and abdominal pain were reported.
Conclusions: Garenoxacin with its superior yet differentiated pharmacodynamic and pharmacokinetic profi le involving low minimum
inhibitory concentrations with high target site tissue concentrations defi nitely fi nds a merit for further evaluation. With superior safety
profi le, excellent antimicrobial coverage and a convenient once a day dosing garenoxacin appears to improve the patient compliance.
Description
Keywords
Garenoxacin, Infection, Urinary tract infections
Citation
Pukar M, Hajare A, Krishnaprasad K, Bhargava A. Post-Approval, Observational Study with Garenoxacin a Newer des-fl uoroquinolone in Uncomplicated Urinary Tract Infections in Vadodara, India. IJSS Journal of Surgery 2015 Jan-Feb; 1(1): 1-4.